The effect of nedocromil sodium on human eosinophil activation.
Nedocromil sodium inhibited the increase in eosinophil activation (measured by IgG- and complement-dependent cytotoxicity assays) induced by platelet activating factor (PAF). Inhibition of the upregulation in eosinophil effector function by nedocromil sodium was dose-dependent (optimal at 10(-7) mol/L) and paralleled that produced by a specific PAF antagonist, BN 52021. In addition, preliminary data suggest that nedocromil sodium can inhibit the increase in IgG-dependent release of LTC4 from human eosinophils after stimulation with the synthetic tripeptide, formyl-methionyl-leucyl-phenylalanine (fMLP). These data support our previous hypothesis that part of the mode of action of nedocromil sodium may be due to its ability to directly block the chemotactic factor-induced enhancement of inflammatory cell activity.
Moqbel
R
R
Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom.
Cromwell
O
O
Kay
A B
AB
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D017835:Nedocromil; D010587:Phagocytosis / Q000187:drug effects; D010972:Platelet Activating Factor / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010972:Platelet Activating Factor; D015363:Quinolones; D017835:Nedocromil